Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction | Zendy

Barry M. Massie | Zendy; Peter E. Carson | Zendy; John J.V. McMurray | Zendy; Michel Komajda | Zendy; Robert S. McKelvie | Zendy; Michael R. Zile | Zendy; Susan Anderson | Zendy; Mark Donovan | Zendy; Erik Iverson | Zendy; C Staiger | Zendy; Agata Ptaszynska | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction

Author(s) -

Barry M. Massie,

Peter E. Carson,

John J.V. McMurray,

Michel Komajda,

Robert S. McKelvie,

Michael R. Zile,

Susan Anderson,

Mark Donovan,

Erik Iverson,

C Staiger,

Agata Ptaszynska

Publication year - 2008

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa0805450

Subject(s) - irbesartan , medicine , hazard ratio , heart failure , ejection fraction , cardiology , myocardial infarction , angina , stroke (engine) , placebo , confidence interval , blood pressure , mechanical engineering , alternative medicine , pathology , engineering

Approximately 50% of patients with heart failure have a left ventricular ejection fraction of at least 45%, but no therapies have been shown to improve the outcome of these patients. Therefore, we studied the effects of irbesartan in patients with this syndrome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research